Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy

Lung cancer remains one of today’s most deadly and intractable cancers. Non-small cell lung cancer (NSCLC) accounts for roughly 85% of lung cancers, with an extremely poor survival rate. To ensure patient comfort and survival, the development of a selective therapy is imperative. However, lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Rohan, Krishnan, Venkat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447734/
https://www.ncbi.nlm.nih.gov/pubmed/28611939
http://dx.doi.org/10.3389/fonc.2017.00104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447734/
https://www.ncbi.nlm.nih.gov/pubmed/28611939
http://dx.doi.org/10.3389/fonc.2017.00104

Ejemplares similares